Initial Stroke Analysis
Group 29: Helena Møller, Emma Christiansen, Casper Harreby, Frederik Holmstrup, and Laura Christiansen
Introduction
The International Stroke Trial v. 2 data
- Assessing efficacy and safety of antithrombotic therapy compared to control.
- Antithrombotic agents: Aspirin and subcutaneous Heparin.
Ischaemic stroke and treatments
- Ischaemic stroke: Medical condition in which poor blood flow to a part of the brain causes cell death
Project Aim
- Assessing effects of antithrombotics (heparin and aspirin) for recurrent ischaemic strokes
Methods
Raw data:
- 19435 observations with 112 variables.
01_load:
- Data has been loaded and saved in a tsv-file.
02_clean:
- Global syntax of NA, and Y/N for binary variables.
- Global syntax for the use of numbers 1-8 as to describe causes of death.
- Correction of errors made when the data was collected.
- Removal of column determined to be irrelevant.
- Merging of columns for easier data analysis.
- Data was split and re-joined into one.
03_augment
- Groups created based on different treatments, and different doses of aspirin and heparin.
Descriptive analysis
- Observations/patients: 19,435
- Variables: 98
- Treatment groups: 6
![]()
Data visualization: Events during first 14 days
- Patients receiving higher heparin doses and asprin are more frequent in cerebral bleed/haemorrhagic stroke group
- Likewise, higher heparin doses and aspirin patients are more represented in patients with indicator of non-cerebral bleed
- Patient group receiving no trial medication had more subjects with indicator of pulmonary embolism
Data visualization: type of stroke
Data visualization: effects of treatments